Dapagliflozin Tablet
Product Images NDC 70748-105

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 70748-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 01)

Chemical structure of dapagliflozin, showing its molecular framework with hydroxyl groups, a chlorine-substituted benzene ring, and an ethoxy group attached to the phenyl ring. This illustration represents the active ingredient of Dapagliflozin tablets.*

FDA Label Image

Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 02)

A scatter plot illustrating the relationship between dapagliflozin dose (mg) on a logarithmic scale and glucose excretion in 24-hour urinary glucose (g). The plot distinguishes observed values for healthy subjects and subjects with type 2 diabetes mellitus (T2DM) using different symbols, along with fitted lines for each group showing dose-response trends.*

FDA Label Image

Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 03)

A line graph depicting adjusted mean percentage changes in HbA1c from baseline over 24 study weeks for Dapagliflozin tablets 10 mg, Dapagliflozin tablets 10 mg combined with Metformin, and Metformin alone. The graph shows data points and trends comparing these treatments in reducing HbA1c levels in participants who completed the study without rescue therapy.*

FDA Label Image

Figure 3: Adjusted Mean Change From Baseline Over Time In Hba1c (%) In A 24-week Placebo- Controlled Trial Of Dapagliflozin Tablets In Combination With Metformin (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 04)

A line graph comparing HbA1c (%) adjusted mean change from baseline over 24 weeks for two groups: placebo plus metformin, and dapagliflozin tablets 10 mg plus metformin. The y-axis shows change from baseline, and the x-axis shows study weeks. The graph includes a scatter plot for week 24 with error bars representing 95% confidence intervals.*

FDA Label Image

Image4 (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 05)

A Kaplan-Meier curve showing the percentage of patients with an event over time in months from randomization. The graph compares Dapagliflozin with placebo, indicating a consistently lower percentage of patients with events in the Dapagliflozin group. The number of patients at risk at various time points is listed below the graph for both groups.*

FDA Label Image

Image 5 (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 06)

A line graph comparing the percentage of patients with a specific event over a 60-month period between Dapagliflozin and placebo groups. The x-axis represents months from randomization, and the y-axis shows patients with the event in percent. Patient numbers at risk are listed below the x-axis for both groups.*

FDA Label Image

Dapagliflozin Tabletsrx Only5mgndc 70748-105-0630 Tablets Bottle Label (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 07)

Dapagliflozin Tablets 5 mg oral tablets label by Lupin Pharmaceuticals, Inc. The label indicates 30 tablets per package with an NDC of 70748-105-06. It includes storage instructions, a note for the pharmacist to dispense the medication guide, and manufacturing details citing Lupin Limited, India. A QR code is also present linking to additional medication information.*

FDA Label Image

Dapagliflozin Tabletsrx Only10 mgndc 70748-106-0630 Tablets Bottle Label (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 08)

Label for Dapagliflozin Tablets 10 mg oral tablets, manufactured by Lupin Pharmaceuticals, Inc. The label shows the NDC 70748-106-06, indicates a package size of 30 tablets, and includes storage instructions and a QR code for the medication guide. It states that each tablet contains 10 mg dapagliflozin and includes disclaimers for pharmacists.*

FDA Label Image

Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 331 1)

Dapagliflozin 5 mg oral tablets packaged in a white and blue blister card. The card holds 14 round tablets arranged in two rows. Labeler Lupin Pharmaceuticals, Inc. is indicated on the packaging.*

FDA Label Image

Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 333 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.